Analysis of the DNA Binding Activity of BRCA1 and Its Modulation by the Tumour Suppressor p53 by Naseem, Riffat & Webb, Michelle
Analysis of the DNA Binding Activity of BRCA1 and Its
Modulation by the Tumour Suppressor p53
Riffat Naseem
1, Michelle Webb
2*
1Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University, Cardiff, United Kingdom, 2Centre for Molecular Medicine, Department of
Medical Genetics, School of Medicine, University of Manchester, Manchester, United Kingdom
Abstract
Background: The breast cancer susceptibility protein, BRCA1 functions to maintain the integrity of the genome. The exact
mechanisms by which it does so, however, remain unclear. The ability of BRCA1 to bind directly to DNA suggests a more
direct role. However, little research has been conducted to understand the functional relevance of this characteristic of
BRCA1. In this study we examine the DNA substrate specificity of BRCA1 and how this may be controlled by one of its
interacting partners, p53.
Methodology/Principal Findings: Using competition gel retardation assays we have examined the ability of residues 230-
534 of BRCA1 to discriminate between different synthetic DNA substrates that mimic those recognised by the DNA damage
response i.e. four-way junction DNA, mismatch containing DNA, bulge containing DNA and linear DNA. Of those tested the
highest affinity observed was for four-way junction DNA, with a 20 fold excess of each of the other synthetic DNA’s unable
to compete for any of the bound BRCA1 230-534. We also observed a higher affinity for C:C and bulge containing DNA
compared to linear duplex and G:T containing DNA. BRCA1 230-534 also has interaction sites for the tumour suppressor p53
and we show that titration of this complex into the DNA binding assays significantly reduces the affinity of BRCA1 for DNA.
Conclusions/Significance: In this paper we show that BRCA1 can discriminate between different types of DNA damage and
we discuss the implications of this with respect to its function in DNA repair. We also show that the DNA binding activity can
be inhibited by the tumour suppressor p53 and suggest that this may prevent genome destabilizing events such as HR
between non-homologous sequences.
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Introduction
Cellular and environmental agents that interact with and
modify the chemical structure of DNA constantly undermine the
integrity of the human genome. The BRCA1 protein, which is
associated with hereditary breast and ovarian cancer, acts as a
scaffold that both organises and coordinates a number proteins
involved in maintaining genome integrity [1,2]. This is illustrated
by the formation of a dynamic multiprotein BRCA1 Associated
Genome Surveillance Complex (BASC) [2]. The BASC complex is
characterised by a high number of factors that are involved in the
DNA damage response, for example the mismatch repair
complexes MLH1-PMS2 and MSH2–MSH6, the NBS1-
MRE11-RAD50 complex which participates in pathways associ-
ated with the repair of double strand breaks and the global
damage sensor ATM.
BRCA1 is a large protein of 1863 amino acids that, with the
exception of an N-terminal RING domain and two tandem C-
terminal BRCT domains [3], bears little homology to any other
known protein. The structures of both of these domains have been
determined and not only provide insights into their functional
significance but also provide a structural framework for under-
standing cancer causing mutations [4,5]. The RING domain has
been identified in a number of proteins associated with targeted
protein degradation through ubiquitination [6]. Association of the
RING domains of BRCA1 with that of BARD1 results in the
formation of a heterodimer which functions as an active E3
ubiquitin ligase [7]. The BRCT domain has been found in
numerous proteins that function in the cellular response to DNA
damage [8] and indeed this region of BRCA1 interacts with a
number of proteins involved in such processes [9–11]. Although
largely unfolded [12,13] the central region of BRCA1 has
interaction sites for a number of proteins that are associated with
maintaining genome integrity (e.g. p53 [14], RAD50 [15],
FANCA [16], BRCA2 [17]) and also distorted DNA structures
that occur as a result of the repair of double strand breaks by
homologous recombination [18,12]. This region also contains
interaction sites for RAD51 [19], which catalyses strand invasion
of the homologous undamaged DNA molecule during the repair of
double strand breaks by homologous recombination. BRCA1
associates directly with RAD51 and both co-localise to discrete
sub-nuclear foci that redistribute to sites of DNA damage under
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ed H2AX (cH2AX) in response to double strand breaks [21]. The
formation of cH2AX foci is an early event in the DNA damage
response occurring within 10 min. BRCA1 is detectable in these
foci 30 min thereafter [21].
Functional support for the participation of BRCA1 in the DNA
damage response is presented by studying the phenotypic outcome
of targeted Brca1 deletions. For example mouse embryonic stem
(ES) cells nullizygous for Brca1 show spontaneous chromosome
breakage, profound genomic instability and hypersensitivity to a
variety of damaging agents, e.g. c radiation all of which suggests a
defect in DNA repair [22–24].
The precise role BRCA1 plays in DNA repair is poorly
understood. This is in part due to the lack of any identifiable
functional domains. Therefore, in this present study we have used
a soluble fragment of BRCA1, residues 230-534, to investigate the
DNA binding specificity of BRCA1 and its interaction with the
tumour suppressor p53.
Results
Structure specific DNA binding of BRCA1 230-534
Previously we reported the identification and characterisation of
a soluble region of BRCA1 (residues 230-534) that selectively
bound to four-way junction DNA when compared to linear duplex
DNA [12]. The ability of BRCA1 to recognise distorted DNA
structures, suggests that it may play an important role in DNA
damage recognition during the repair response. Therefore, we
have examined further the DNA structure selectivity of BRCA1
230-534 by assessing its relative binding affinity for a range of
DNA substrates recognised in DNA repair (figure 1). In particular
we have synthesised substrates that mimic those formed during the
repair of double strand breaks by homologous recombination
(four-way junction DNA) and those recognised by the mismatch
repair machinery (G:T, C:C and bulge containing DNA), as
BRCA1 is known to participate in these pathways [2,25]. The
design of the mismatched oligonucleotides was based upon that of
Alani et al [26] and Degtyareva et al [27] as they showed that the
presence of triple lesions significantly amplified the binding signal
in gel retardation assays. Furthermore, clusters of mismatches are
frequently left behind after recombination between two similar
DNA’s.
In gel retardation assays where increasing amounts of BRCA1
230-534 were titrated against each of the DNA substrates a single
protein DNA complex was observed (figure 2) with initial results
suggesting the highest affinity for four-way junction DNA. To
study the relative binding affinities of BRCA1 230-534 in more
detail competition gel retardation assays were performed in which
BRCA1 230-534 was bound to radiolabelled four-way junction
DNA and competed with unlabelled linear, C:C, G:T and bulge
containing DNA. It is clear from figure 3 a–d that none of the
competitors were unable to disrupt the BRCA1 230-534 four way
junction complex even when present at 20 fold molar excess (lane
8). In competition assays where BRCA1 230-534 was bound to
radiolabelled linear duplex DNA (figure 3 e–h) equimolar
concentrations of G:T, bulge and C:C containing DNA reduced
the amount of bound BRCA1 230-534 by 49%, 65% and 70%
respectively. At equimolar concentrations a reduction of 50%
would represent equal binding affinities. As expected the most
effective competitor was four-way junction DNA reducing the
binding of BRCA1 230-534 by 91%. These data suggest a binding
preference order of four-way junction.C:C.bulge.GT=linear
duplex DNA.
The tumour suppressor p53 interacts with the DNA
binding interface of BRCA1
It has been reported that residues 224–500 of BRAC1 form a
complex with the tumour suppressor p53 both in vivo and in vitro
[14]. Therefore, we investigated the possibility that the physical
association of p53 with BRCA1 may modulate its DNA binding
activity. The binding of p53 to BRCA1 230-534 was first
confirmed in a glutathione S-transferase (GST) pull down assay.
A GST fusion of p53 was bound to glutathione sepharose beads
and incubated with purified BRCA1 230-534. This resulted in the
Figure 1. DNA substrates used to analyse the binding specificity of BRCA1 230-534.
doi:10.1371/journal.pone.0002336.g001
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addition of boiling SDS (figure 4), indicating that BRCA1 230-534
not only binds to the distorted DNA structures described earlier
but also p53. In the control experiment no binding of BRCA1
230-534 was observed to glutathione sepharose beads alone (data
not shown).
To determine if the interaction of p53 was able to modulate the
DNA binding activity of BRCA1 it was titrated against BRCA1
230-534 bound to bulge, C:C mismatch and four-way junction
DNA (figure 5 a–c). Upon titration of p53 there is a clear
reduction in the DNA binding affinity of BRCA1 230-534 to all
substrates. Since no p53 binding is observed to C/C mismatch and
bulged DNA this reduction in affinity can only be attributed to its
interaction with BRCA1 230-534. P53 binding to four-way
junction DNA has been reported previously [28] and as expected
p53 bound to four-way junction DNA in the absence of BRCA1.
However, a 50% reduction of BRCA1 230-534 binding is
observed at a concentration where p53 is unable to bind (compare
lane 4 and 8 in figure 5c). These data suggest that p53 suppresses
the DNA binding activity of BRCA1.
Discussion
BRCA1 is a large scaffolding protein that co-ordinates the
appropriate protein-protein interactions and/or posttranslational
modifications required for effective signal transduction upon DNA
damage. This is illustrated by the formation of the multiprotein
Figure 2. Gel retardation analysis of BRCa1 230-534 with BRCA1
was incubated with 32P labelled (a) linear duplex DNA (b) G:T
mismatch DNA (c) C:C mismatch DNA, (d) Bulge containing DNA
and (e) four-way junction DNA. Ineach, lane1 containsfree DNA, and
lanes 2–5 contain 1,2,4 and 5 mM of BRCA1 230-534 respectively. The
concentrationoflabelledDNA in each was0.5 mM.Gelswerevisualisedby
autoradiography and quantified by densitometry.
doi:10.1371/journal.pone.0002336.g002
Figure 3. Competition gel retardation analysis of BRCA1 230-534 bound to four-way junction DNA (a–d) and linear duplex DNA (e–
h). In each, lane 1 contains free DNA, lane 2 no competitor and lanes 3–8 contain 0.25, 0.5, 0.75, 1, 5 and 10 mM of each of the competitors shown.
The concentration of labelled DNA and BRCA1 230-534 were 0.5 mM and 5 mM respectively. Gels were visualised by autoradiography and quantified
by densitometry.
doi:10.1371/journal.pone.0002336.g003
Figure 4. GST pull-down analysis of the interaction of BRCA1
230-534 with p53. Purified GST-p53 was absorbed onto a Glutathione
Sepharose column and incubated with purified BRCA1 230-534 (lane 1).
After washes with 100, 300 and 500 mM NaCl (lanes 3–5 respectively)
bound BRCA1 230-534 was eluted with SDS sample buffer (lanes 6 and
7). Unbound BRCA1 230-534 was analysed in lane 2. Samples were
analysed in 12% SDS PAGE gels and visualised by silver staining.
doi:10.1371/journal.pone.0002336.g004
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for the ATM and ATR dependent phosphorylation of p53, c-Jun,
NBS, CtIP, Smc1 and Chk 2 [1], key regulators of the DNA
damage response.
In this present study we have shown that BRCA1 230-534 binds
selectively to a number of structured DNA substrates recognised
by the DNA damage response i.e. four-way junction DNA, bulge
containing DNA and C:C mismatch DNA. We also confirm its
association with the tumour suppressor p53 as indicated by other
researchers [13,14] and show that this interaction suppresses the
DNA binding activity of BRCA1.
In the repair of double strand breaks (DSB) by homologous
recombination the broken DNA is resected to yield a 39 single-strand
overhang that invades a homologous donor duplex and results in the
formation of a four-way junction type structure known as a Holliday
junction [29]. BRCA1 230-534 shows very strong selectivity for this
intermediate structure (at least 20 fold) and we propose that the
integral DNA binding activity of BRCA1 is required for the effective
targeting of BRCA1 mediated complexes to regions of the
chromosome undergoing homologous recombination repair
(HRR). During recombination mismatches and small insertions/
deletion can arise as a result of strand exchange between moderately
divergent (homologous) sequences [30]. The increased preference of
BRCA1 for the 2 bp bulged and C:C mismatch DNA substrates
compared to linear duplex and G:T DNA may represent a
mechanism by which these lesions are sensed and repair proteins
targetedtoensurethefidelityofHRR.The lackofspecificityforG:T
containing DNA compared to other lesions can be explained by the
association of BRCA1 with the mismatch repair protein complex
MSH2–MSH6inthe BASC complex [2]. MSH2–MSH6 recognises
G:T mismatches with up 20 fold higher affinity than other
mismatches, in particular C:C [31]. Furthermore, insertion/
deletions of 1 bp and .10 bp are recognised better then
intermediates of 2–8 bp [31]. Therefore, the MSH2–MSH6
complex potentially targets G:T mismatches that occur during
strand exchange negating the need for this activity of BRCA1.
Although the biological outcome of inhibiting the DNA binding
activity of BRCA1 needs to be clarified we can speculate that it
may represent a mechanism for p53 transcription independent
suppression of the repair of double strand breaks by homologous
recombination [32,33], perhaps to prevent genome destabilizing
events such as HR between non-homologous sequences. Mecha-
nisms that inhibit HR between divergent sequences while
permitting recombination between identical sequences are vital
as they enable repair without risking genome re-arrangement. P53
has been shown by several groups to be important in this process
and while its exact role has yet to be defined it is, however,
independent of MSH2 [32] a mismatch repair protein which
recognises mismatches that occur during heteroduplex formation
between two non-complementary DNAs. Furthermore, it cannot
be explained in terms of RAD51 depletion as knockdown of p53
by RNAi has no effect on the levels of RAD51 [32]. However,
there is a suggestion that p53 represses HR through physical
interaction with RAD51. P53 prevents stimulation of HR by wild
type RAD51 but not by a RAD51 mutant that displays reduced
binding to p53 [33]. The functions of other protein involved in
HR are also inhibited by interaction with p53, for instance the
helicase activities of BLM and WRN [34] and the single stranded
binding activity of RPA [35]. The inhibition of the DNA binding
activity of BRCA1 by the direct association with p53 may,
therefore, prevent HR between non-homologous DNAs ensuring
the fidelity of DNA repair. Another outcome of inhibiting the
DNA binding activity may be to promote apoptosis by preventing
repair under conditions of extreme DNA damage. Indeed the
physical association of BRCA1 and p53 when transfected into
SW480 cells results in an increase in apoptosis [14]. Furthermore
p53 prevents the rapid assembly of BLM-deficient BRCA1/NBS1
complexes at the stalled replication forks and induces the apoptotic
response independent of its transactivation activity [36].
In summary we have shown that BRCA1 selectively targets sites
of HRR potentially through its integral DNA binding activity and
that this function of BRCA1 may be regulated by the tumour
suppressor p53. With over 100 disease causing mutations
identified in BRCA 230-534 it is easy to see how disruption of
the DNA binding activity may contribute to tumour development
through loss of genome integrity.
Materials and Methods
Purification of BRCA1 230-534 and p53
BRCA1 230-534 was over expressed from pET22b in the E. coli
BL21 DE3 codon plus and purified following published proce-
dures. The tumour suppressor p53 was over expressed as a GST
fusion from pGEX2TKp53 (a kind gift from Tony Kouzaradies) in
BL21 (DE3) codon plus. The p53-GST fusion was purified using
Glutathione Sepharose according to the manufacturer’s protocol
(GE Healthcare). The experiments were carried out with the
uncleaved GST fusion protein.
Preparation of DNA substrates
Synthetic oligonucleotides were purchased from MWG Biotech.
The sequences are given in Figure 1. Annealing was promoted by
Figure 5. P53 reduces the DNA binding affinity of BRCA1.
Titration of p53 against BRCA1 230-534 bound (a) C:C mismatch
containing DNA (b) bulge containing DNA and (c) four-way junction
DNA. In all, lane 1 contains free DNA, lane 2 contains bound BRCA1230-
534 with no p53 and lanes 3–6 contain 100, 200, 300 and 500 nM p53
respectively. Lanes 7–10 contain no BRCA1 230-534 and 100, 200, 300
and 500 nM p53 respectively. Samples were analysed in 6% polyacryl-
amide gels and visualised by autoradiography.
doi:10.1371/journal.pone.0002336.g005
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with subsequent cooling to 4uC at a rate of 1uC/min in annealing
buffer (10 mM Tris-HCl, 50 mM NaCl). The oligonucleotides
were 59-end labelled with [32P]ATP using T4 polynucleotide
kinase (NEB). Unincorporated label was removed using a 1 ml
G50 (GE Healthcare) spin column.
Gel retardation assays
Gel retardation assays (10 ml) were performed in binding buffer
(50 mM NaCl, 10 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 1 mM
dithiothreitol, 5% glycerol) using 0.5 mM of each of the 32P-
labelled DNA substrates. Samples were incubated at room
temperature before analysis in 6% polyacrylamide gels. Gels were
pre-electrophoresed at 150 V for 40 min, vacuum dried and
visualised by autoradiography.
Competition gel retardation assays
Binding reactions typically contained 500 nM labelled DNA,
5 mM protein 50 mM NaCl, 10 mM Tris-HCl (pH 8.0), 0.5 mM
EDTA 1 mM dithiothreitol, 5% glycerol and increasing concen-
trations of competitor DNA in a final reaction volume of 10 ml.
Competitor DNAs, 0.25, 0.5, 0.75, 1, 5 and 10 mM, were added at
the start of the incubation reaction. The reactions were analysed in
6% non-denaturing polyacrylamide gels in 16 TAE buffer, pre-
run for 60 min at 100 V, and electrophoresed at 150 V for
,40 min at 4uC. Protein–DNA complexes were visualised by
autoradiography.
P53 binding assays
Purified p53 and BRCA1 230-534 were incubated with
Glutathione Sepharose beads at room temperature for 1 hr in
10 mM Na phosphate (pH 7), 1 mM DTT, 1 mM EDTA,
50 mM NaCl. The beads were washed 3 times with the same
buffer but containing 100 mM 300 mM and 500 mM NaCl.
Bound BRCA1 230-534 was eluted by the addition of boiling SDS
loading buffer. Each stage was monitored by analysis in 12% SDS
polyacrylamide gels. To determine if p53 was able to modulate the
DNA binding activity it was titrated at concentrations of 100 nM,
200 nM, 300 nM and 500 nM against BRCA1 230-534 bound to
C:C, bulge and four-way junction DNA in 50 mM NaCl, 10 mM
Tris-HCl (pH 8.0), 0.5 mM EDTA 1 mM dithiothreitol, 5%
glycerol. In all cases the concentration of labelled DNA and
BRCA1 230-534 were 0.5 mM and 3 mM respectively. The
reactions were analysed in 6% non-denaturing TAE polyacryl-
amide gels, pre-run for 60 min at 100 V, and electrophoresed at
150 V for ,40 min at 4uC. Protein–DNA complexes were
visualised by autoradiography.
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